The Global Burden of Disease Study (GBD) began 30 years ago with the goal of providing timely, valid and relevant assessments of critical health outcomes. Over this period, the GBD has become progressively more granular. The latest iteration provides assessments of thousands of outcomes for diseases..., injuries and risk factors in more than 200 countries and territories and at the subnational level in more than 20 countries. The GBD is now produced by an active collaboration of over 8,000 scientists and analysts from more than 150 countries. With each GBD iteration, the data, data processing and methods used for data synthesis have evolved, with the goal of enhancing transparency and comparability of measurements and communicating various sources of uncertainty. The GBD has many limitations, but it remains a dynamic, iterative and rigorous attempt to provide meaningful health measurement to a wide range of stakeholders.
more
Global cardiovascular disease (CVD) burden is high and rising, especially in low-income and middle-income countries (LMICs). Focussing on 45 LMICs, we aimed to determine (1) the adult population’s median 10-year predicted CVD risk, including its variation within countries by socio-demographic char...acteristics, and (2) the prevalence of self-reported blood pressure (BP) medication use among those with and without an indication for such medication as per World Health Organization (WHO) guidelines.
more
Cardiovascular diseases, principally ischemic heart disease (IHD), are the most important cause of death and disability in the majority of low- and lower-middle-income countries (LLMICs). In these countries, IHD mortality rates are significantly greater in individuals of a low socioeconomic status (...SES).
Three important focus areas for decreasing IHD mortality among those of low SES in LLMICs are (1) acute coronary care; (2) cardiac rehabilitation and secondary prevention; and (3) primary prevention. Greater mortality in low SES patients with acute coronary syndrome is due to lack of awareness of symptoms in patients and primary care physicians, delay in reaching healthcare facilities, non-availability of thrombolysis and coronary revascularization, and the non-affordability of expensive medicines (statins, dual anti-platelets, renin-angiotensin system blockers). Facilities for rapid diagnosis and accessible and affordable long-term care at secondary and tertiary care hospitals for IHD care are needed. A strong focus on the social determinants of health (low education, poverty, working and living conditions), greater healthcare financing, and efficient primary care is required. The quality of primary prevention needs to be improved with initiatives to eliminate tobacco and trans-fats and to reduce the consumption of alcohol, refined carbohydrates, and salt along with the promotion of healthy foods and physical activity. Efficient primary care with a focus on management of blood pressure, lipids and diabetes is needed. Task sharing with community health workers, electronic decision support systems, and use of fixed-dose combinations of blood pressure-lowering drugs and statins can substantially reduce risk factors and potentially lead to large reductions in IHD. Finally, training of physicians, nurses, and health workers in IHD prevention should be strengthened.
more
The Indigenous tribe called the Wiwa lives retracted in the Sierra Nevada de Santa Marta, Colombia. Little is known about their health status and whether the health care system in place covers their needs.
Lesson on schistosomiasis (bilharziasis): Causes, Symptoms and Treatment. Schistosomiasis is caused by parasitic blood flukes from the genus schistosoma. Schistosoma cercariae penetrate human skin and enter the bloodstream of the infected individual, where the parasites enter the portal vein. Schist...osoma parasites also enter the mesenteric and bladder circulations, where they release eggs. Symptoms of schistosomiasis are related to the location of the parasites, the parasite burden and the amount of eggs produced. Systems affected in schistosomiasis include the hepatic, splenic, genitourinary, pulmonary, and nervous systems.
more
Objective
To estimate the prevalence of Chagas disease in pregnant women and the vertical transmission of the disease.
Methods
Observational studies were identified from eight electronic databases, and details on study design, population and prevalence of Chagas disease were extracted. The data... were pooled using a random-effects model, and choropleth maps were created based on geopolitical regions and countries.
more
Chagas disease constitutes a public health problem, and Spain is the non-endemic country with the highest burden of disease outside the Americas. It represents a model for non-endemic countries regarding health policies to control the disease. This study is aimed to generate estimates of the T.cruzi... prevalence and the number of undetected and untreated individuals with the infection in Spain and to compare them with the actual number of cases reported by official sources.
more
23 April 2020EMA/202483/2020 Rev
Chloroquine and hydroxychloroquine are known to potentially cause heart rhythm problems, and these could be exacerbated if treatment is combined with other medicines, such as the antibiotic azithromycin, that have similar effects on the heart.
Public Health & Primary Care / Research Article
Cogent Medicine (2018), 5: 1430197
Lefebvre et al., Cogent Medicine (2018), 5: 1430197 https://doi.org/10.1080/2331205X.2018.1430197
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002514 March 1, 2018
Research Article
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002625 July 31, 2018 / 1-19
PLoS Med 15(7): e1002615. https://doi.org/10.1371/journal. pmed.1002615
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002462 November 28, 2017
Research Article
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002374 August 8, 2017
Published: March 28, 2017https://doi.org/10.1371/journal.pmed.1002271
PLoS Med 14(3): e1002271. https://doi.org/10.1371/journal.pmed.1002271
March 28, 2017https://doi.org/10.1371/journal.pmed.1002274
PLoS Med 14(3): e1002274. https://doi.org/10.1371/journal.pmed.1002274
Research Article
PLOS Medicine | DOI:10.1371/journal.pmed.1002253 April 4, 2017
PLOS Medicine | DOI:10.1371/journal.pmed.1002088 August 23, 2016